Ovarian cancer gene therapy: Repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 3, 2000, Pages 553-559

  Al Hendy, Ayman ^b   Magliocco, Anthony M ^c   Al Tweigeri, Taher ^c   Braileanu, George ^c   Crellin, Natasha ^c   Li, Hui ^a   Strong, Theresa ^a   Curiel, David ^a   Chedrese, P Jorge ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c NONE

Author keywords

Adenovirus; Antibodies; Gene therapy; Ovarian cancer

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME;

EID: 0006121301     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.104837     Document Type: Article

References (25)

1. 1. American College of Obstetricians and Gynecologists. Ovarian cancer. Washington: The College; 1998. Educational Bulletin No.: 250.
2. 2. National Institutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up. Gynecol Oncol 1994;55(3 Pt 2):S4-14.
3. 3. Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest 1997;43:268-75.
4. 4. Barnes MN, Deshane JS, Rosenfield M, Siegal GP, Curiel DT, Alvarez RD. Gene therapy and ovarian cancer: a review. Obstet Gynecol 1997;89:145-55.
5. 5. Harris JD, Gutierrez AA, Hurst HC, Sikora K, Lemoine NR. Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994;1:170-5.
6. 6. Matthews T, Boehme R. Antiviral activity and mechanism of action of ganciclovir. Rev Infect Dis 1988;10 Suppl 3:S490-4.
7. 7. Culver KW, Ram Z, Wallbridge N, Ishii H, Oldfield EH, Blease RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
8. 8. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995;92:2577-81.
9. 9. Chen SH, Shine HD, Goodman JC, Grossman RG, Woo SL. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci U S A 1994;91:3054-7.
10. 10. Kozarsky KF, Wilson JM. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
11. 11. Kaplan JM, St George JA, Pennington SE, Keyes LD, Johnson RP, Wadsworth SC, et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 1996;3:117-27.
12. 12. Bouvet M, Fang B, Ekmekcioglu S, Ji L, Bucana CD, Hamada K, et al. Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther 1998;5:189-95.
13. 13. DeMatteo RP, Markmann JF, Kozarsky KF, Barker CF, Raper SE. Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther 1996;3:4-12.
14. 14. Ilan Y, Sauter B, Chowdhury NR, Reddy BV, Thummala NR, Droguett G, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenoviruses. Hepatology 1998;27: 1368-76.
15. 15. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 1996;3:154-62.
16. 16. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVGAR-3) with androgen and estrogen receptors. Cancer Res 1983;43:5379-89.
17. 17. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-Cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn J Cancer Res 1989;80:459-63.
18. 18. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-72.
19. 19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-81.
20. 20. Fu X, Hoffman RM. Human ovarian carcinoma metastatic models constructed in nude mice by orthotopic transplantation of histologically-intact patient specimens. Anticancer Res 1993; 13:283-6.
21. 21. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994; 91:4348-52.
22. 22. Gjersten MK, Saeterdal I, Beiske K, Gaudernack G. Antigen-presenting function of human peritoneum mesothelial cells isolated from a pancreatic carcinoma patient after mutant Ras peptide vaccination. Cancer Immunol Immunother 1996; 43:262-8.
23. 23. Visser CE, Brouwer-Steenbergen JJ, Schadee-Eestermans IL, Meijer S, Krediet RT, Reelen RH. Ingestion of Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli by human peritoneal mesothelial cells. Infect Immun 1996; 64: 3425-8.
24. 24. McGuire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 1996;334:1-6.
25. 25. Brand K, Arnold W, Bartels T, Lieber A, Kay MA, Strauss M, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther 1997;4:9-16.